4ET1103

Developed for: neuropathy, painful
Investigated by: 4E Therapeutics · National Institute of Neurological Disorders and Stroke (NINDS)

today NCT07586514 · Ph 1

2026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT07586514	Apr → Aug 2025	neuropathy, painful	4E Therapeutics	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	4ET1103	“The study drug (4ET1103 or placebo) will be administered orally under fasting condition.” NCT07586514 ↗
Action	Inhibit	“MNK inhibitor for treatment of neuropathic pain” NCT07586514 ↗
Route	Oral	“will be administered orally under fasting condition” NCT07586514 ↗